{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:14:59Z","timestamp":1790266499568,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.pbb.2019.172757","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T19:38:30Z","timestamp":1565379510000},"page":"172757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents"],"prefix":"10.1016","volume":"185","author":[{"given":"Misae","family":"Takakuwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketoshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Kagaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kotera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pbb.2019.172757_bb0005","doi-asserted-by":"crossref","first-page":"e00241","DOI":"10.1002\/prp2.241","volume":"4","author":"Arakawa","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.pbb.2019.172757_bb0010","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bbr.2016.09.043","article-title":"Dopamine D1 signaling involvement in the effects of the phosphodiesterase 10A inhibitor, PDM-042 on cognitive function and extrapyramidal side effect in rats","volume":"317","author":"Arakawa","year":"2017","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.pbb.2019.172757_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/bph.12906","article-title":"Dopamine receptors - IUPHAR review 13","volume":"172","author":"Beaulieu","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2019.172757_bb0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neuropharm.2017.11.045","article-title":"NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update","volume":"142","author":"Cadinu","year":"2018","journal-title":"Neuropharmacology"},{"issue":"Suppl. 1","key":"10.1016\/j.pbb.2019.172757_bb0025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4088\/JCP.13049su1c.04","article-title":"Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains","volume":"75","author":"Citrome","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172757_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2019.06.008","article-title":"Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone","author":"Corponi","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"Suppl. 3","key":"10.1016\/j.pbb.2019.172757_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.15032su1","article-title":"The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence","volume":"77","author":"Correll","year":"2016","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.pbb.2019.172757_bb0040","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1517\/14740338.2016.1167873","article-title":"Relationship between antipsychotic medication, serum prolactin levels and osteoporosis\/osteoporotic fractures in patients with schizophrenia: a critical literature review","volume":"15","author":"De Hert","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"issue":"4","key":"10.1016\/j.pbb.2019.172757_bb0045","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/JCP.0000000000001047","article-title":"A proof-of-concept study evaluating the phosphodiesterase 10A inhibitor PF-02545920 in the adjunctive treatment of suboptimally controlled symptoms of schizophrenia","volume":"39","author":"DeMartinis","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2019.172757_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevNeurobiol.v14.i1.10","article-title":"Cognitive impairment in schizophrenia is the core of the disorder","volume":"14","author":"Elvevag","year":"2000","journal-title":"Crit. Rev. Neurobiol."},{"key":"10.1016\/j.pbb.2019.172757_bb0055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bcp.2017.05.009","article-title":"Challenges and opportunities for the development of new antipsychotic drugs","volume":"143","author":"Forray","year":"2017","journal-title":"Biochem. Pharmacol."},{"issue":"26","key":"10.1016\/j.pbb.2019.172757_bb0060","doi-asserted-by":"crossref","first-page":"18438","DOI":"10.1074\/jbc.274.26.18438","article-title":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)","volume":"274","author":"Fujishige","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.pbb.2019.172757_bb0065","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1046\/j.1432-1327.1999.00963.x","article-title":"Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A","volume":"266","author":"Fujishige","year":"1999","journal-title":"Eur. J. Biochem."},{"issue":"6","key":"10.1016\/j.pbb.2019.172757_bb0070","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0898-6568(02)00146-8","article-title":"Comparison of enzymatic characterization and gene organization of cyclic nucleotide phosphodiesterase 8 family in humans","volume":"15","author":"Gamanuma","year":"2003","journal-title":"Cell. Signal."},{"issue":"6","key":"10.1016\/j.pbb.2019.172757_bb0075","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/14737175.2017.1268531","article-title":"Phosphodiesterase 10 inhibitors in clinical development for CNS disorders","volume":"17","author":"Geerts","year":"2017","journal-title":"Expert. Rev. Neurother."},{"issue":"Suppl. 2","key":"10.1016\/j.pbb.2019.172757_bb0080","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1590\/1516-4446-2013-1164","article-title":"Animal models for predicting the efficacy and side effects of antipsychotic drugs","volume":"35","author":"Gobira","year":"2013","journal-title":"Rev. Bras. Psiquiatr."},{"issue":"2","key":"10.1016\/j.pbb.2019.172757_bb0085","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.pbb.2019.172757_bb0090","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1017\/S1092852919000531","article-title":"68 cognitive impairment in schizophrenia. First-generation long-acting antipsychotics versus aripiprazole long-acting injectable","volume":"24","author":"Guillena","year":"2019","journal-title":"CNS Spectr."},{"issue":"6","key":"10.1016\/j.pbb.2019.172757_bb0095","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.neuint.2011.07.002","article-title":"Cariprazine (RGH-188), a potent D3\/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents","volume":"59","author":"Gyertyan","year":"2011","journal-title":"Neurochem. Int."},{"issue":"3","key":"10.1016\/j.pbb.2019.172757_bb0100","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1248\/cpb.c17-00783","article-title":"Discovery of 2-[(E)-2-(7-fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine hydrochloride as a highly selective PDE10A inhibitor","volume":"66","author":"Kadoh","year":"2018","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"issue":"Suppl. 4","key":"10.1016\/j.pbb.2019.172757_bb0105","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1016\/S0924-977X(01)00109-2","article-title":"Extrapyramidal side effects are unacceptable","volume":"11","author":"Kane","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2019.172757_bb0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/13543776.2012.739157","article-title":"Phosphodiesterase 10A inhibitors: a 2009\u20132012 patent update","volume":"23","author":"Kehler","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"issue":"2","key":"10.1016\/j.pbb.2019.172757_bb0115","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/138161211795049624","article-title":"PDE10A inhibitors: novel therapeutic drugs for schizophrenia","volume":"17","author":"Kehler","year":"2011","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"10.1016\/j.pbb.2019.172757_bb0120","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1006\/bbrc.1999.1013","article-title":"Characterization and phosphorylation of PDE10A2, a novel alternative splice variant of human phosphodiesterase that hydrolyzes cAMP and cGMP","volume":"261","author":"Kotera","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.pbb.2019.172757_bb0125","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0006-2952(00)00457-3","article-title":"Characterization and effects of methyl-2-(4-aminophenyl)-1, 2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4, 5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5)","volume":"60","author":"Kotera","year":"2000","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.pbb.2019.172757_bb0130","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1517\/14656566.7.8.1005","article-title":"Current schizophrenia drugs: efficacy and side effects","volume":"7","author":"Krebs","year":"2006","journal-title":"Expert. Opin. Pharmacother."},{"issue":"2","key":"10.1016\/j.pbb.2019.172757_bb0135","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00213-011-2567-y","article-title":"Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test","volume":"221","author":"Langen","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2019.172757_bb0140","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.schres.2018.08.028","article-title":"A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia","volume":"204","author":"Macek","year":"2019","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.pbb.2019.172757_bb0145","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0893-133X(01)00368-2","article-title":"Neuropharmacological profile of a novel potential atypical antipsychotic drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)-6H-[1]benzothieno[2,3-b][1,5] benzodiazepine maleate)","volume":"26","author":"Morimoto","year":"2002","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2019.172757_bb0150","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1006\/bbrc.2000.2661","article-title":"Identification of human PDE7B, a cAMP-specific phosphodiesterase","volume":"271","author":"Sasaki","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.pbb.2019.172757_bb0155","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","article-title":"Immunohistochemical localization of PDE10A in the rat brain","volume":"985","author":"Seeger","year":"2003","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.pbb.2019.172757_bb0160","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/0929867043456043","article-title":"New antipsychotics and schizophrenia: a review on efficacy and side effects","volume":"11","author":"Serretti","year":"2004","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.pbb.2019.172757_bb0165","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1124\/jpet.115.230482","article-title":"The phosphodiesterase 10A selective inhibitor TAK-063 improves cognitive functions associated with schizophrenia in rodent models","volume":"356","author":"Shiraishi","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"31","key":"10.1016\/j.pbb.2019.172757_bb0170","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.2174\/1381612819666131216115417","article-title":"Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment","volume":"20","author":"Snyder","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.pbb.2019.172757_bb0175","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/978-3-319-58811-7_14","article-title":"PDE inhibitors for the treatment of schizophrenia","volume":"17","author":"Snyder","year":"2017","journal-title":"Adv. Neurobiol."},{"issue":"12","key":"10.1016\/j.pbb.2019.172757_bb0180","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.96.12.7071","article-title":"Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A","volume":"96","author":"Soderling","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.pbb.2019.172757_bb0185","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/cns.12798","article-title":"TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia","volume":"24","author":"Suzuki","year":"2018","journal-title":"CNS Neurosci. Ther."},{"issue":"3","key":"10.1016\/j.pbb.2019.172757_bb0190","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/jpet.114.218552","article-title":"In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents","volume":"352","author":"Suzuki","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.pbb.2019.172757_bb0195","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1038\/npp.2016.20","article-title":"TAK-063, a PDE10A inhibitor with balanced activation of direct and indirect pathways, provides potent antipsychotic-like effects in multiple paradigms","volume":"41","author":"Suzuki","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2019.172757_bb0200","first-page":"69","article-title":"Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme","volume":"10","author":"Thompson","year":"1979","journal-title":"Adv. Cyclic Nucleotide Res."},{"issue":"8","key":"10.1016\/j.pbb.2019.172757_bb0205","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1742-1241.2007.01416.x","article-title":"Metabolic side effects of antipsychotic medication","volume":"61","author":"Tschoner","year":"2007","journal-title":"Int. J. Clin. Pract."},{"issue":"3","key":"10.1016\/j.pbb.2019.172757_bb0210","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2174\/138161210790170085","article-title":"Conditioned avoidance response in the development of new antipsychotics","volume":"16","author":"Wadenberg","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.pbb.2019.172757_bb0215","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.neuroscience.2005.12.042","article-title":"Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase","volume":"139","author":"Xie","year":"2006","journal-title":"Neuroscience"},{"issue":"40","key":"10.1016\/j.pbb.2019.172757_bb0220","doi-asserted-by":"crossref","first-page":"31469","DOI":"10.1074\/jbc.M003041200","article-title":"Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression","volume":"275","author":"Yuasa","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"29","key":"10.1016\/j.pbb.2019.172757_bb0225","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.2174\/0929867325666180309110629","article-title":"Phosphodiesterase 10 inhibitors - novel perspectives for psychiatric and neurodegenerative drug discovery","volume":"25","author":"Zagorska","year":"2018","journal-title":"Curr. Med. Chem."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009130571930334X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009130571930334X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:35:32Z","timestamp":1758774932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009130571930334X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":45,"alternative-id":["S009130571930334X"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2019.172757","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2019.172757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"172757"}}